Bouchard 1998.

Methods	Allocation: randomised (no further description). Blindness: none, open label. Duration: 2 years. Consent: not stated. Setting: need trial for update.
Participants	Diagnosis: schizophrenia (PANSS score 60‐120). N=184. Age: not stated. Sex: not stated. History: 81% outpatients.
Interventions	1. Risperidone: mean dose 5.5 mg/day. N=93. 2. Classical neuroleptics: mean dose 1mg/day chlorpromazine equivalents. N=91.
Outcomes	Clinical improvement: 20% reduction in PANSS. Leaving the study early. Unable to use ‐ Global effect: CGI score (no data). Subjective tolerance: ESRS Part 1 (insufficient data). Movement disorders: ESRS Part 2 (insufficient data).
Notes	Ongoing study ‐ 12 month data only.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear